Neurological biomarkers help in objectively measuring and evaluating normal biological and pathogenic processes. These aid in detecting neurological disorders, assessing risk, tracking disease progression, and measuring response to therapeutic interventions. Rising incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and others can boost demand for reliable neurological biomarkers. Furthermore, growing focus on development of precision medicine and companion diagnostics for neurological conditions can drive the market growth. However, limited understanding of disease biology and lack of consensus on use of biomarkers can pose challenge to market growth.

Market Dynamics:

Global neurological biomarkers market growth is primarily driven by rising prevalence of neurological disorders globally. According to the data from WHO, neurological disorders affect over a billion people worldwide with neurological conditions being a major contributor to the global burden of disease. Growing geriatric population, prone to these disorders, can boost demand. Higher investments in biomarker research and drug development by pharmaceutical players can drive the market growth. However, high cost of drug development from target identification to commercialization hampers newer biomarkers from entering the market. Lack of consensus on use of biomarkers in diagnosis and clinical decision-making can hamper the market growth.  Increasing public private collaborations for interdisciplinary research can offer market growth opportunities.

Key Features of the Study:

• This report provides in-depth analysis of the global neurological biomarkers market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neurological biomarkers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Qiagen, Thermo Fisher Scientific and Abbott Laboratories
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global neurological biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

• By Biomarker Type:
  
  • Artificial Tears 
  • Imaging Biomarkers  
  • Metabolomics Biomarkers 
  • Proteomic Biomarkers 
  • Genomics Biomarkers
• By Application
  
  • Alzheimer’s Disease 
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorders
  • Others
•  By End User
  • Hospital Laboratories
  • Clinical Diagnostic Centers
  • Research Organizations
  • Others
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Thermo Fisher Scientific Inc.
  • Merck & Co., Inc.
  • Bio-Rad Laboratories, Inc.
  • AbbVie Inc.
  • QIAGEN N.V.
  • Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Myriad RBM
  • Quanterix Corporation
  • PerkinElmer Inc.
  • Fujirebio
  • Alzheon, Inc.
  • Diagenic ASA
  • Psynova Neurotech Ltd
  • Banyan Biomarkers, Inc.
  • Cisbio Bioassays
  • Athena Diagnostics
  • Immuno-Biological Laboratories Co., Ltd.